Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
IPO Year: 2014
Exchange: NASDAQ
Website: bellicum.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2022 | $5.00 | Buy | Ladenburg Thalmann |
Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals with a rating of Buy and set a new price target of $5.00
15-12G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
8-K - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
POS AM - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
POS AM - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company's assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most recent patient treated in the Phase 1/2 trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) experienced serious immune-mediated adverse events including Grade 4 cytokine rel
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled "Early Results from a Phase 1, Multicent
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.14 per share and vest over four years, with 25% of the shares vesting on the one-year a
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer. Details of the poster presentation are as follows: Title: Early Results from a
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for today at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial. The poster titled "Abrogation of Immune Effector Cell Neurotoxicity Syndrome (
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update. "We are encouraged by the progress we are making in our patient enrollment efforts for the BPX-601 and BPX-603 trials despite a national fludarabine shortage, and are on track to present data updates for both programs in the first half of 2023," said Rick Fair, President and Chief Executive Officer. "We are also excited about new data from the Baylor College of Medicine supporting the potential benefit of CaspaCIDe® in resolvin
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 31, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.06 per share and vest over four years, with 25% of the shares vesting on the one-year a
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally. Details regarding Bellicum's presentation at the conference are as follows: Event: 2022 Cell & Gene Meeting on the Mesa Date: October 11, 2022Time: 4:30 p.m. PT Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011 Virtual attendance is available which includes a livestream of Bellicum's presentation and the ability to v
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of September 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.20 per share and vest over four years, with 25% of the shares vesting on the one-yea
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The comp
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an operational update. "In the third quarter, Bellicum broadened the potential impact of its CaspaCIDe technology through an additional licensing agreement with MD Anderson," said Rick Fair, President and
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
3 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
Gainers Minerva Surgical (NASDAQ:UTRS) shares increased by 111.8% to $0.42 during Friday's regular session. As of 13:30 EST, Minerva Surgical's stock is trading at a volume of 85.0 million, which is 3814.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $74.9 million. CNS Pharma (NASDAQ:CNSP) stock rose 20.44% to $2.18. CNS Pharma's stock is trading at a volume of 1.6 million shares as of 13:30 EST. This is 48.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.0 million. Kala Pharmaceuticals (NASDAQ:KALA) stock moved upwards by 18.57% to $17.62. As of 13:30 EST, this security is trading
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design. Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gained 67% to $0.3225. VIQ Solutions Inc. (NASDAQ:VQS) shares jumped 49.1% to $0.3474. Marker Therapeutics, Inc. (NASDAQ:MRKR) climbed 31% to $1.73 after the company reported pre-clinical data of its MT-601 multiTAA-specific T cell product candidate MT-601 in lymphoma cells. Tenax Therapeutics, Inc. (NASDAQ:TENX) rose 30% to $0.4151. Tenax Therapeutics achieved major milestone as USPTO granted notice of allowance fo
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 98.9% to $0.37 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.2 million. VistaGen Therapeutics (NASDAQ:VTGN) stock increased by 38.98% to $0.19. The market value of their outstanding shares is at $40.8 million. Marker Therapeutics (NASDAQ:MRKR) shares increased by 30.83% to $1.74. The market value of their outstanding shares is at $15.3 million. Tenax Therapeutics (NASDAQ:TENX) stock moved upwards by 25.06% to $0.4. The market value of their outstanding shares is at $8.7 million. Freeline Therapeutics (NASDAQ:FRLN) shares moved upwards by 15.99% to $2.9. The market value of th
Gainers VIQ Solutions Inc. (NASDAQ:VQS) shares rose 66.8% to $0.3887 in pre-market trading. Appreciate Holdings, Inc. (NASDAQ:SFR) shares surged 59% to $0.4307 in pre-market trading after dropping 14% on Tuesday. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) shares rose 50% to $0.2009 in pre-market trading. Vistagen will present fasedienol safety and exploratory efficacy data from Phase 3 Open-label social anxiety disorder study at the American Society for Clinical Psychopharmacology Annual Meeting. WANG & LEE GROUP, Inc. (NASDAQ:WLGS) gained 27.3% to $1.77 in pre-market trading after declining around 5% on Tuesday. LL Flooring Holdings, Inc. (NYSE:LL) shares gained 19.1% to $4.93 in pr
Gainers GSI Technology, Inc. (NASDAQ:GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16, 2023. ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares jumped 82.8% to $8.27 after the company reported the FDA's Advisory Committee voted in support of favorable benefit-risk assessment for neffy in the treatment of severe allergic reactions (Type 1), including anaphylaxis. Getaround, Inc. (NYSE:GETR) shares climbed 73.6% to $0.5749 after the company announced it is acquiring substantially all of the assets of HyreCar for an aggregate purchase price of $9.45 million. Dermata Therapeutics, Inc.
Gainers Getaround, Inc. (NYSE:GETR) shares surged 112% to $0.7020 in pre-market trading. Getaround acquired substantially all assets of HyreCar for an aggregate purchase price of $9.45 million. Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares rose 35.2% to $2.61 in pre-market trading after the company highlighted recent corporate progress, and reported financial results for the first quarter. Blue Bird Corporation (NASDAQ:BLBD) shares gained 30% to $25.16 in pre-market trading after the company reported better-than-expected Q2 results. Rubicon Technologies, Inc. (NYSE:RBT) shares rose 19.5% to $0.5340 in pre-market trading after dropping around 15% on Thursday. Momentus Inc. (NASDAQ:M
Gainers TScan Therapeutics (NASDAQ:TCRX) stock rose 122.3% to $5.0 during Tuesday's regular session. The current volume of 41.6 million shares is 104202.1% of TScan Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $123.1 million. Novavax (NASDAQ:NVAX) stock rose 37.04% to $10.21. The current volume of 33.2 million shares is 585.1% of Novavax's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $879.8 million. The company's, Q1 earnings came out today. Voyager Therapeutics (NASDAQ:VYGR) stock moved upwards by 34.11% to $11.14. The current
Gainers TScan Therapeutics, Inc. (NASDAQ:TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. ClearOne, Inc. (NASDAQ:CLRO) climbed 66.1% to $2.06 after the company announced a special one-time cash dividend of $1.00 per share of common stock, payable May 31 to shareholders of record on May 22, 2023. Ensysce Biosciences, Inc. (NASDAQ:ENSC) gained 52.8% to $5.26 after the company announced completion of PF614-MPAR-101, a clinical study examining its first pain medication with overdose protection, PF614-MPAR. Mobiquity Technologies, Inc. (NASDAQ:MOBQ) climbed 48.5% to $0.2302 after gaining around 7% on Monday
Gainers TScan Therapeutics (NASDAQ:TCRX) stock rose 61.8% to $3.64 during Tuesday's pre-market session. The company's market cap stands at $89.6 million. Erytech Pharma (NASDAQ:ERYP) stock increased by 47.49% to $1.18. The company's market cap stands at $36.5 million. Ensysce Biosciences (NASDAQ:ENSC) stock increased by 42.15% to $4.89. The market value of their outstanding shares is at $6.2 million. Synlogic (NASDAQ:SYBX) stock moved upwards by 23.21% to $0.69. The company's market cap stands at $46.7 million. Novavax (NASDAQ:NVAX) shares rose 20.93% to $9.01. The company's market cap stands at $776.4 million. As per the press release, Q1 earnings came out today. Tactile Systems Tech
Gainers Mobiquity Technologies, Inc. (NASDAQ:MOBQ) gained 74.2% to $0.2701 in pre-market trading after gaining around 7% on Monday. ClearOne, Inc. (NASDAQ:CLRO) gained 46.7% to $1.82 in pre-market trading after the company announced a special one-time cash dividend of $1.00 per share of common stock, payable May 31 to shareholders of record on May 22, 2023. Tivic Health Systems, Inc. (NASDAQ:TIVC) gained 20.3% to $0.1565 in pre-market trading. Tivic Health, on Monday, launched a B2B portal. Palantir Technologies Inc. (NYSE:PLTR) surged 19% to $9.21 in pre-market trading after the company reported strong Q1 results and said it expects to remain profitable each quarter through the end o